LNAI vs LRMR

Lunai Bioworks Inc. vs Larimar Therapeutics, Inc. — Valuation Comparison 2026

LNAI

Biotechnology
Lunai Bioworks Inc.
Quality
2.9
out of 10
Value Trap
41
WARN
Price
$3.04
Last close
Models
5/13
Active
VS

LRMR

Biotechnology
Larimar Therapeutics, Inc.
Quality
4.8
out of 10
Value Trap
36
LOW
Price
$3.49
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType LNAI Fair ValueLNAI Upside LRMR Fair ValueLRMR Upside
Bayesian DCF Intrinsic $0.84 -72.4% $1.86 -46.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.82 -47.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $6.31 +107.4% $3.75 +7.6%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for LNAI vs LRMR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LNAI vs LRMR — Which Stock Is More Undervalued?

LRMR scores higher with a 4.8/10 quality rating vs LNAI's 2.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Lunai Bioworks Inc. (LNAI) and Larimar Therapeutics, Inc. (LRMR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LNAI currently trades at $3.04 with a QOC of 2.9/10, while LRMR trades at $3.49 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).